Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Mayo Clinic |
---|---|
Information provided by: | Mayo Clinic |
ClinicalTrials.gov Identifier: | NCT00588458 |
The reason for this study is to see if a new radiologic technique called computerized tomographic cholangiography (CT cholangiography) could be helpful to demonstrate the bile ducts features and measure the amount of space of bile duct canals that should be filled with bile fluid. It may be useful to find out how well these findings correlate with the previously known clinical predictors in term of the clinical outcomes that will happen in the future for patients with primary sclerosing cholangitis (PSC).
Condition | Intervention | Phase |
---|---|---|
Primary Sclerosing Cholangitis |
Procedure: CT cholangiography |
Phase II |
Study Type: | Interventional |
Study Design: | Open Label, Single Group Assignment |
Official Title: | Primary Sclerosing Cholangitis: Value of Computerized Tomographic Cholangiography and Intraductal Volumetric Measurement in Determining the Prognosis |
Estimated Enrollment: | 20 |
Study Start Date: | March 2007 |
Estimated Study Completion Date: | March 2009 |
Estimated Primary Completion Date: | March 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
single arm: Experimental
All patients with PSC in will have CT cholangiography.
|
Procedure: CT cholangiography
Cholografin 20ml will be diluted in 100 ml of normal saline and infused over 30 minute time interval. Following the infusion of the cholografin, morphine (0.04 mg/kg) will be administered to contract the sphincter of Oddi and improve bile duct distension and visualization. Thirty minutes following the administration of morphine a test scan (CT cholangiography) will be performed through the liver to determine if there is adequate biliary excretion. The test scan will consist of 10 mm thick image obtained through the mid liver. If there is evidence of biliary excretion, high-resolution images will be performed through the liver and bile ducts. The axial images will be reconstructed into maximum intensity projection models and volume rendered models that can be viewed in 3-dimension.
|
Prognostic models, which have been produced based on clinical, histological and biochemical feature, are useful in predicting survival and determining timing for liver transplantation. Preliminary feasibility studies in patients with PSC using high resolution CT with a contrast agent (CT cholangiography), has shown excellent depiction of bile ducts. CT cholangiography also has the potential to allow quantification of intraductal volume by using sophisticated computer programs. This assessment may be an important clinical feature to assess disease severity and progression.The information about cholangiographic features could be important for therapeutic decisions (e.g., in determining the usefulness of balloon dilatation or stenting for a dominant extrahepatic duct stricture), for counseling patients, and for therapeutic trials in stratifying patients and assessing efficacy of treatment.
Ages Eligible for Study: | 18 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Mayo Clinic and Foundation ( Phunchai Charatcharoenwitthaya, M.D. ) |
Study ID Numbers: | 06-002976 0 |
Study First Received: | December 26, 2007 |
Last Updated: | November 3, 2008 |
ClinicalTrials.gov Identifier: | NCT00588458 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Primary sclerosing cholangitis Computed tomographic cholangiography MELD score Mayo risk score for PSC |
Morphine Cholangitis Digestive System Diseases Cholangitis, Sclerosing |
Bile Duct Diseases Biliary Tract Diseases Primary Sclerosing Cholangitis |
Cholangitis Digestive System Diseases Cholangitis, Sclerosing Bile Duct Diseases Biliary Tract Diseases |